School of Medicine


Showing 541-550 of 1,084 Results

  • Eldrin F. Lewis, MD, MPH

    Eldrin F. Lewis, MD, MPH

    Simon H. Stertzer, MD, Professor

    BioDr. Lewis is a board-certified, fellowship-trained specialist in cardiovascular medicine. He is the chief of the Division of Cardiovascular Medicine and a professor of cardiovascular medicine.

    Dr. Lewis is an esteemed clinician-scientist who specializes in the care of patients with advanced heart failure. He is an internationally recognized expert on heart failure, heart transplant, and quality of life for heart failure patients. He cares deeply about his patients as well as his colleagues, the hospital, and the School of Medicine. Dr. Lewis is committed to diversity and inclusion, as well as expanding Stanford clinical research initiatives.

    A fundamental principle of Dr. Lewis’ practice is his belief that “there is more to life than death,” that cardiovascular care should go beyond helping patients survive to also helping them enjoy the best possible quality of life.

    Dr. Lewis has deep expertise in conducting clinical trials examining diagnostic and therapeutic approaches to heart failure. He has done innovative work to create systems for incorporating quality of life measures for cardiovascular patients into electronic health records. This research has received support from the National Heart, Lung and Blood Institute and the National Institutes of Health.

    Much of his quality of life research has focused on patient-reported outcomes. Dr. Lewis emphasizes the importance of looking at how a disease, whether chronic or acute, impacts people’s ability to function and perform their activities of daily living. Strategies to improve patients’ well-being focus not only on their physical symptoms but also on depression, anxiety, exercise capacity, and ability to function in daily living.

    Dr. Lewis’ commitment to expanding clinical research initiatives will give patients more opportunities to participate in the clinical trials and access the latest care strategies that can translate into better outcomes. The goal is early access to the most advanced technology, pharmacology, and device therapy that can change outcomes for the better. He also envisions forming closer partnerships with community cardiologists and capitalizing further on Stanford’s proximity to and unique relationships with the digital technology leaders of Silicon Valley to enhance the use of digital technology for monitoring patients, optimizing treatment, and tracking outcomes.

    He has authored nearly 200 articles published in peer-reviewed journals including the New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, JAMA Cardiology, JAMA Internal Medicine, and many more. He is also on multiple editorial boards for cardiovascular journals and was an associate editor for Circulation–Heart Failure. In addition, he is an author of professional society clinical practice guidelines and scientific statements from both the American Heart Association (AHA) and the Food and Drug Administration.

    Dr. Lewis’ honors for clinical care, scholarship, and research include the Joel Gordon Miller Award for community service and leadership from the University of Pennsylvania School of Medicine. He also was one of the first recipients of the Minority Faculty Development Award, which recognizes the research potential of young physicians. Dr. Lewis has received a grant from the Robert Wood Johnson Foundation to study the role of quality of life assessment in clinical decision making in patients with heart failure.

    He is a fellow of the American College of Cardiology and the National American Heart Association (AHA) Research Committee. In addition, Dr. Lewis was as a member of the AHA Founders Affiliate Board of Directors, chair of the Council on Clinical Cardiology, and research chair of the Association of Black Cardiologists. He also serves on scientific committees to review grants for the AHA and on the FDA Task Force for the Standardization of Definitions for Endpoint Events in Cardiovascular Trials.

  • Daniel Yuhang Li

    Daniel Yuhang Li

    Instructor, Medicine - Cardiovascular Medicine

    BioI am a physician scientist in the Division of Cardiology at Stanford. My clinical interest is at the intersection of inflammation, autoimmunity and cardiovascular disease in a field called 'Cardio-Rheumatology'. Patients with rheumatologic diseases typically have an elevated cardiovascular disease risk profile along with an insidious onset. Moreover, with the ever-expanding biologic drug formulary for patients, it is important for us to characterize the cardiovascular effects of these medications. In my research, I believe that understanding how inflammatory and autoimmune mechanisms modify coronary artery disease can help us develop a novel perspective towards treating atherosclerosis beyond lipid lowering. My research goal is to advance novel therapeutics for atherosclerosis by leveraging my expertise in genetics, computational biology, and experience with diverse model organism perturbation models. My strategy employs a ‘systems’ approach, starting with human population variations at the genetic level and integrating findings across RNA, protein, and model organism studies. This comprehensive synthesis aims to grasp the overarching biological narrative, thereby facilitating the development of translational therapies that transform concepts from bench to bedside.

  • Ron Li

    Ron Li

    Clinical Associate Professor, Medicine

    BioRon Li is a Clinical Associate Professor of Medicine in the Division of Hospital Medicine and Center for Biomedical Informatics Research at Stanford University School of Medicine. As the Medical Informatics Director for Digital Health at Stanford Health Care, he provides medical and informatics direction for the health system's enterprise digital health portfolio, including expanding digital referral networks and virtual care modalities. He is the co-founder and Director for the Stanford Emerging Applications Lab (SEAL), which helps clinicians and staff build ideas into novel digital products that are prototyped and tested for care delivery at Stanford Health Care.

    Ron's academic interests focus on the "delivery science" of new technological capabilities such as digital and artificial intelligence in healthcare and how to design, implement, and evaluate new tech enabled models of care delivery. Ron's work spans across multiple disciplines, including clinical medicine, data science, digital health, information technology, design thinking, process improvement, and implementation science. He has consulted for various companies in the digital health and artificial intelligence space. He is an attending physician on the inpatient medicine teaching service at Stanford Hospital and is the Associate Program Director for the Stanford Clinical Informatics Fellowship.

  • David Liang, MD, PhD

    David Liang, MD, PhD

    Professor of Medicine (Cardiovascular) at the Stanford University Medical Center, Emeritus

    BioStanford researchers are creating a micro-device that physicians could guide through the body to help diagnose and treat clogged arteries and other diseases. Tethered to the outside world by a thin wire, a tiny machine creeps through blood vessels, searching out deadly plaques and obliterating them with a zap of a laser. While a laser will come later, for now David Liang, MD, PhD, is focusing on a tiny eye that could give physicians an unprecedented view into blood vessels.

  • Charles Liao

    Charles Liao

    Clinical Assistant Professor, Medicine

    Current Research and Scholarly InterestsEducational Curriculum: Working with Professional Interpreters